Skip to main content

Table 1 Patient demographics and tumor characteristics of whole cohort, derivation whole cohort, derivation cohort and validation cohort

From: Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion

Variables

Whole cohort (n = 903)

Derivation cohort (n = 679)

Validation cohort (n = 224)

P value

Age, years

   

0.869

  > 60

270 (29.9)

204 (30.0)

66 (29.5)

 

  ≤ 60

633 (70.1)

475 (70.0)

158 (70.5)

 

Sex

   

0.743

 Male

772 (85.5)

579 (85.3)

193 (86.2)

 

 Female

131 (14.5)

100 (14.7)

31 (13.8)

 

HBsAg

   

0.339

 Positive

760 (84.2)

576 (84.8)

184 (82.1)

 

 Negative

143 (15.8)

103 (15.2)

40 (17.9)

 

HBeAg

   

0.522

 Positive

255 (28.2)

188 (27.7)

67 (29.9)

 

 Negative

648 (71.8)

491 (72.3)

157 (70.1)

 

HBV-DNA, IU/mL

   

0.847

  > 104

392 (43.4)

296 (43.6)

96 (42.9)

 

  ≤ 104

511 (56.6)

383 (56.4)

128 (57.1)

 

Antiviral therapy

   

0.274

 Yes

431 (47.7)

317 (46.7)

114 (50.9)

 

 No

472 (52.3)

362 (53.3)

110 (49.1)

 

PT, s

   

0.180

  > 13

333 (36.9)

242 (35.6)

91 (40.6)

 

  ≤ 13

570 (63.1)

437 (64.4)

133 (59.4)

 

T-Bil, μmol/L

   

0.580

  > 17.1

261 (28.9)

193 (28.4)

68 (30.4)

 

  ≤ 17.1

642 (71.1)

486 (71.6)

156 (69.6)

 

ALB, g/L

   

0.152

  > 40

351 (38.9)

273 (40.2)

78 (34.8)

 

  ≤ 40

552 (61.1)

406 (59.8)

146 (65.2)

 

ALT, U/L

   

0.324

  > 40

318 (35.2)

233 (34.3)

85 (37.9)

 

  ≤ 40

585 (64.8)

446 (65.7)

139 (62.1)

 

AST, U/L

   

0.119

  > 40

383 (42.4)

278 (40.9)

105 (46.9)

 

  ≤ 40

520 (57.6)

401 (59.1)

119 (53.1)

 

GGT, U/L

   

0.509

  > 60

350 (38.8)

259 (38.1)

91 (40.6)

 

  ≤ 60

553 (61.2)

420 (61.9)

133 (59.4)

 

Ascites

   

0.719

 Yes

95 (10.5)

70 (10.3)

25 (11.2)

 

 No

808 (89.5)

609 (89.7)

199 (88.8)

 

Child-Pugh grade

   

0.793

 A

839 (92.9)

630 (92.8)

209 (93.3)

 

 B

64 (7.1)

49 (7.2)

15 (6.7)

 

AFP, ng/mL

   

0.218

  > 400

312 (34.6)

227 (33.4)

85 (37.9)

 

  ≤ 400

591 (65.4)

452 (66.6)

139 (62.1)

 

CSPH

   

0.388

 Yes

95 (10.5)

68 (10.0)

27 (12.1)

 

 No

808 (89.5)

611 (90.0)

197 (87.9)

 

Tumour size, cm

   

0.054

  > 5

486 (53.8)

353 (52.0)

133 (59.4)

 

  ≤ 5

417 (46.2)

326 (48.0)

91 (40.6)

 

Tumour number

   

0.114

 Multiple

191 (21.2)

152 (22.4)

39 (17.4)

 

 Single

712 (78.8)

527 (77.6)

185 (82.6)

 

Cirrhosis

   

0.760

 Yes

403 (44.6)

305 (44.9)

98 (43.8)

 

 No

500 (55.4)

374 (55.1)

126 (56.3)

 

Tumor differentiation

   

0.060

 Grade III or IV

420 (46.5)

328 (48.3)

92 (41.1)

 

 Grade I or II

483 (53.5)

351 (51.7)

132 (58.9)

 

Tumor encapsulation

   

0.678

 Complete

485 (53.7)

362 (53.3)

123 (54.9)

 

 None/incomplete

418 (46.3)

317 (46.7)

101 (45.1)

 

Microvascular invasion

   

0.195

 Yes

331 (36.7)

257 (37.8)

74 (33.0)

 

 No

572 (63.3)

422 (62.2)

150 (67.0)

 

Satellite nodules

   

0.600

 Yes

77 (8.5)

56 (8.2)

21 (9.4)

 

 No

826 (91.5)

623 (91.8)

203 (90.6)

 

Necrosis

   

0.959

 Yes

473 (52.4)

356 (52.4)

117 (52.2)

 

 No

430 (47.6)

323 (47.6)

107 (47.8)

 

Resection margin, cm

   

0.816

  > 1

86 (9.5)

64 (9.4)

22 (9.8)

 

  ≤ 1

817 (90.5)

615 (90.6)

202 (90.2)

 

Operation time, min

   

0.384

  > 200

365 (40.4)

280 (41.2)

85 (37.9)

 

  ≤ 200

538 (59.6)

399 (58.8)

139 (62.1)

 

Blood loss, mL

   

0.661

  > 400

244 (27.0)

186 (27.4)

58 (25.9)

 

  ≤ 400

659 (73.0)

493 (72.6)

166 (74.1)

 

Blood transfusion

   

0.380

 Yes

99 (11.0)

78 (11.5)

21 (9.4)

 

 No

804 (89.0)

601 (88.5)

203 (90.6)

 

Extent of resection

   

0.391

 Major resection

361 (40.0)

266 (39.2)

95 (42.4)

 

 Minor resection

542 (60.0)

413 (60.8)

129 (57.6)

 
  1. Abbreviations: HBsAg hepatitis B surface antigen, HBeAg hepatitis Be antigen, HBV-DNA hepatitis B virus DNA load, PT prothrombin time, T-Bil total bilirubin, ALB albumin, ALT alanine transaminase, AST aspartic aminotransferase, GGT γ-glutamyl transpeptadase, AFP α-fetoprotein, CSPH clinically significant portal hypertension